---
schema_version: "secwatch.filing_event.v1"
accession: "0002019410-26-000053"
form_type: "8-K"
ticker: "CAI"
cik: "0002019410"
company_name: "Caris Life Sciences, Inc."
filed_at: "2026-08-05T20:12:27+00:00"
generated_at: "2026-08-05T20:14:45.173591+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Caris Life Sciences Q2 revenue up 45% to $263.7M; raises FY 2026 guidance to $1.03-1.04B

## Summary
- Revenue $263.7M (+45% YoY); net loss narrowed to $0.6M from $71.8M loss; positive Adj. EBITDA $55.7M.
- Clinical cases ~59,200 (+18% YoY); gross margin improved 500 bps to 68%.
- Raised 2026 revenue guidance to $1.03-1.04B (27-28% growth); reaffirmed ~20% clinical therapy selection volume growth.
- Launched Caris Detect multi-cancer early detection blood test and Caris ChromoSeq for myeloid malignancies.
- Share repurchase program of up to $100M authorized; $82.1M remains available.

## SEC filing metadata
- accession: 0002019410-26-000053
- form_type: 8-K
- ticker: CAI
- cik: 0002019410
- company_name: Caris Life Sciences, Inc.
- filed_at: 2026-08-05T20:12:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/0002019410-26-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000053/cai-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002019410-26-000053
- JSON: https://secwatch.observer/filing/0002019410-26-000053.json
- Plain text: https://secwatch.observer/filing/0002019410-26-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.